Design of Janus Nanoparticles for Mobility Control in Heterogeneous Reservoirs.

Unfavorable mobility ratios in heterogeneous reservoirs have resulted in progressively poor waterflood sweep efficiency and diminishing production. In order to address this issue, our study has developed amphiphilic-structured nanoparticles aimed at enhancing the microscopic displacement capability and oil displacement efficiency. First, the transport process of Janus nanoparticles in porous media was investigated. During the water flooding, Janus nanoparticle injection, and subsequent water flooding stages, the injection pressure increased in a "stepped" pattern, reaching 0.023, 0.029, and 0.038 MPa, respectively. Second, emulsification effects and emulsion viscosity experiments demonstrated that the amphiphilic structure improved the interaction at the oil-water interface, reducing the seepage resistance of the oil phase through emulsification. In porous media, Janus nanoparticles transported with water exhibit 'self-seeking oil' behavior and interact with the oil phase, reducing the viscosity of the oil phase from 19 to 5 mPa·s at 80 °C. Finally, the core model displacement experiment verified the characteristics of Janus nanoparticles in improving the oil-water mobility ratio. Compared with the water flooding stage, the recovery percent increased by 20.8%, of which 13.7% was attributed to the subsequent water flooding stage. Utilizing the asymmetry of the Janus particle structure can provide an effective path to enhanced oil recovery in inhomogeneous reservoirs.

Hyperoside Inhibits RNF8-mediated Nuclear Translocation of ß-catenin to Repress PD-L1 Expression and Prostate Cancer.

BACKGROUND: Hyperoside is a flavonol glycoside isolated from Hypericum perforatum L. that has inhibitory effects on cancer cells; however, its effects on prostate cancer (PCa) remain unclear. Therefore, we studied the anti-PCa effects of hyperoside and its underlying mechanisms in vitro and in vivo. AIM: This study aimed to explore the mechanism of hyperoside in anti-PCa. METHODS: 3-(4,5-Dimethyl-2-Thiazolyl)-2,5-Diphenyl Tetrazolium Bromide (MTT), transwell, and flow cytometry assays were used to detect PCa cell growth, invasion, and cell apoptosis. Immunoblot analysis, immunofluorescence, immunoprecipitation, and quantitative real-time PCR (qRT-PCR) were used to analyze the antitumor mechanism of hyperoside. RESULTS: Hyperoside inhibited PCa cell growth, invasion, and cell cycle and induced cell apoptosis. Furthermore, RING finger protein 8 (RNF8), an E3 ligase that assembles K63 polyubiquitination chains, was predicted to be a direct target of hyperoside and was downregulated by hyperoside. Downregulation of RNF8 by hyperoside impeded the nuclear translocation of ß-catenin and disrupted the Wnt/ß-catenin pathway, which reduced the expression of the target genes c-myc, cyclin D1, and programmed death ligand 1 (PD-L1). Decreased PD-L1 levels contributed to induced immunity in Jurkat cells in vitro. Finally, in vivo studies demonstrated that hyperoside significantly reduced tumor size, inhibited PD-L1 and RNF8 expression, and induced apoptosis in tumor tissues of a subcutaneous mouse model. CONCLUSION: Hyperoside exerts its anti-PCa effect by reducing RNF8 protein, inhibiting nuclear translocation of ß-catenin, and disrupting the Wnt/ß-catenin pathway, in turn reducing the expression of PD-L1 and improving Jurkat cell immunity.